1887

Abstract

Dengue virus (DENV) remains a significant healthcare and socioeconomic burden for endemic countries. Attempts to produce a safe and effective vaccine have been unsuccessful so far, making this task one of the top priorities in the field. We have previously shown that an EDIII-based DNA vaccine is able to induce neutralizing, long-lasting and highly specific antibody responses for all four DENV serotypes in mice using gene-gun delivery technology. Here, we describe the use of recombinant Adeno-associated viral vectors as an alternative DNA delivery platform, in combination with different immunization schedules, to simplify the vaccination protocol without compromising the induction of neutralizing antibody responses. Our results demonstrate that using viral vectored-platforms to deliver genetic vaccines could potentially reduce the number of doses required to induce a sustained DENV-neutralizing response, thus facilitating the implementation and deployment of the vaccine in developing countries.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001351
2019-11-08
2019-11-21
Loading full text...

Full text loading...

References

  1. King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ. Family - Flaviviridae Virus Taxonomy San Diego: Elsevier; 2012; pp 1003– 1020
    [Google Scholar]
  2. Murray NEA, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol 2013;5: 299– 309 [CrossRef]
    [Google Scholar]
  3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW et al. The global distribution and burden of dengue. Nature 2013;496: 504– 507 [CrossRef]
    [Google Scholar]
  4. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med 2018;379: 327– 340 [CrossRef]
    [Google Scholar]
  5. Lindenbach BD, Heinz-Jurgen T, Rice CM. Flaviviridae: the viruses and their replication In Fields BN, Knipe DM, Howley PM. (editors) Fields' Virology, 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007
    [Google Scholar]
  6. Modis Y. Relating structure to evolution in class II viral membrane fusion proteins. Curr Opin Virol 2014;5: 34– 41 [CrossRef]
    [Google Scholar]
  7. Rey FA, Stiasny K, Vaney M-C, Dellarole M, Heinz FX. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep 2018;19: 206– 224 [CrossRef]
    [Google Scholar]
  8. Wahala WMPB, Silva AM de. The human antibody response to dengue virus infection. Viruses 2011;3: 2374– 2395 [CrossRef]
    [Google Scholar]
  9. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010;8: 271– 283 [CrossRef]
    [Google Scholar]
  10. Crill WD, Chang G-JJ. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 2004;78: 13975– 13986 [CrossRef]
    [Google Scholar]
  11. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 2006;80: 9557– 9568 [CrossRef]
    [Google Scholar]
  12. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977;265: 739– 741 [CrossRef]
    [Google Scholar]
  13. Dowd KA, Pierson TC. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 2011;411: 306– 315 [CrossRef]
    [Google Scholar]
  14. Slon Campos JL, Mongkolsapaya J, Screaton GR. The immune response against flaviviruses. Nat Immunol 2018;19: 1189– 1198 [CrossRef]
    [Google Scholar]
  15. Poggianella M, Slon Campos JL, Chan KR, Tan HC, Bestagno M et al. Dengue E protein domain III-based DNA immunisation induces strong antibody responses to all four viral serotypes. PLoS Negl Trop Dis 2015;9: e0003947 [CrossRef]
    [Google Scholar]
  16. Slon Campos JL, Poggianella M, Marchese S, Mossenta M, Rana J et al. DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and yellow fever virus infection. PLoS One 2017;12: e0181734 [CrossRef]
    [Google Scholar]
  17. Slon Campos JL, Poggianella M, Burrone OR. Long-term stability of antibody responses elicited by dengue virus envelope DIII-based DNA vaccines. J Gen Virol 2018;99: 1078– 1085 [CrossRef]
    [Google Scholar]
  18. Mingozzi F, High KA. Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape. Annu Rev Virol 2017;4: 511– 534 [CrossRef]
    [Google Scholar]
  19. Nieto K, Salvetti A. Aav vectors vaccines against infectious diseases. Front Immunol 2014;5: 5 [CrossRef]
    [Google Scholar]
  20. Arsic N, Zacchigna S, Zentilin L, Ramirez-Correa G, Pattarini L et al. Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol Ther 2004;10: 844– 854 [CrossRef]
    [Google Scholar]
  21. Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006;14: 45– 53 [CrossRef]
    [Google Scholar]
  22. Ayuso E, Mingozzi F, Montane J, Leon X, Anguela XM et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther 2010;17: 503– 510 [CrossRef]
    [Google Scholar]
  23. Slon Campos JL, Poggianella M, Marchese S, Bestagno M, Burrone OR. Secretion of dengue virus envelope protein ectodomain from mammalian cells is dependent on domain II serotype and affects the immune response upon DNA vaccination. J Gen Virol 2015;96: 3265– 3279 [CrossRef]
    [Google Scholar]
  24. Petek LM, Fleckman P, Miller DG. Efficient KRT14 targeting and functional characterization of transplanted human keratinocytes for the treatment of epidermolysis bullosa simplex. Mol Ther 2010;18: 1624– 1632 [CrossRef]
    [Google Scholar]
  25. Ussher JE, Taylor JA. Optimized transduction of human monocyte-derived dendritic cells by recombinant adeno-associated virus serotype 6. Hum Gene Ther 2010;21: 1675– 1686 [CrossRef]
    [Google Scholar]
  26. Aldrich WA, Ren C, White AF, Zhou S-Z, Kumar S et al. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. Gene Ther 2006;13: 29– 39 [CrossRef]
    [Google Scholar]
  27. de Souza VAUF, Fernandes S, Araújo ES, Tateno AF, Oliveira OMNPF et al. Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections. J Clin Microbiol 2004;42: 1782– 1784 [CrossRef]
    [Google Scholar]
  28. Khan KH. DNA vaccines: roles against diseases. Germs 2013;3: 26– 35 [CrossRef]
    [Google Scholar]
  29. Vaughn DW, Scherer JM, Sun W. Resistance to infection In Halstead SB. editor Dengue, 1st ed. Imperial College Press; 2008
    [Google Scholar]
  30. Lai C-Y, Tsai W-Y, Lin S-R, Kao C-L, Hu H-P et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008;82: 6631– 6643 [CrossRef]
    [Google Scholar]
  31. Danko JR, Beckett CG, Porter KR. Development of dengue DNA vaccines. Vaccine 2011;29: 7261– 7266 [CrossRef]
    [Google Scholar]
  32. Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T et al. Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 2011;11: 479– 484 [CrossRef]
    [Google Scholar]
  33. Porter KR, Raviprakash K. Nucleic acid (DNA) immunization as a platform for dengue vaccine development. Vaccine 2015;33: 7135– 7140 [CrossRef]
    [Google Scholar]
  34. Choi VW, McCarty DM, Samulski RJ. Host cell DNA repair pathways in adeno-associated viral genome processing. J Virol 2006;80: 10346– 10356 [CrossRef]
    [Google Scholar]
  35. Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A 2013;110: E517– E525 [CrossRef]
    [Google Scholar]
  36. Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014;371: 1994– 2004 [CrossRef]
    [Google Scholar]
  37. Naso MF, Tomkowicz B, Perry WL, Strohl WR. Adeno-Associated virus (AAV) as a vector for gene therapy. BioDrugs 2017;31: 317– 334 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001351
Loading
/content/journal/jgv/10.1099/jgv.0.001351
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error